Related Experiment Video
Updated: Jul 10, 2026
08:13
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
Recombinant factor VIIa: safety and efficacy
Lawrence T Goodnough1, Aryeh S Shander
1Department of Pathology and Medicine, Stanford University, Stanford, California 94305-5626, USA. LTgoodno@stanford.edu
Current Opinion in Hematology
|October 16, 2007
Summary
Recombinant factor VIIa shows hemostatic effects for off-label bleeding but requires more research. Physician discretion guides its use, considering safety and efficacy in diverse patient populations.
Area of Science:
- Hematology
- Pharmacology
Background:
- Recombinant factor VIIa (rFVIIa) is increasingly used off-label for hemostasis.
- This trend raises concerns regarding safety, efficacy, and cost.
Purpose of the Study:
- To review the current evidence on the use of rFVIIa in nonapproved indications.
- To discuss safety, efficacy, and dosing recommendations for off-label rFVIIa use.
Main Methods:
- Literature review of studies on rFVIIa in nonapproved settings.
- Analysis of reported hemostatic effects, adverse events, and dosing strategies.
Main Results:
- rFVIIa demonstrates potential hemostatic effects in post-trauma and perioperative bleeding.
- It may reverse vitamin K antagonist effects and show benefits in liver disease and stroke.
- Caution is advised in hypercoagulable states and disseminated intravascular coagulation.
Conclusions:
- Consensus recommendations exist for off-label rFVIIa use, but further studies are needed for optimal dosing and timing.
- Physician judgment, aided by committees, guides current off-label rFVIIa decisions.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...
01:09Recombinant DNA
Overview